BEDFORD, Mass., Nov 23, 2010 (BUSINESS WIRE) --

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Kevin Quinlan, chief financial officer, will be presenting at the New York Society of Security Analysts (NYSSA) Biotech and Specialty Pharmaceuticals Conference on Tuesday, November 30, 2010. A live audio webcast of the 2:05 p.m. (ET) presentation may be accessed via the "Investors" section of Anika's website at www.anikatherapeutics.com. An archive of the presentation also will be available on the website. At the conference, Mr. Quinlan will discuss the company's business highlights, including the integration of its FAB acquisition.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing, repair and regeneration. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by ORTHOVISC®, a treatment for osteoarthritis of the knee; to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika's Italian subsidiary, Fidia Advanced Biopolymers, S.r.l (FAB), provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. FAB's regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

SOURCE: Anika Therapeutics, Inc.

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., CEO, 781-457-9000
or
Kevin W. Quinlan, CFO, 781-457-9000